Patents by Inventor Davinder Gill
Davinder Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160185859Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: December 16, 2015Publication date: June 30, 2016Applicant: WYETH LLCInventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
-
Patent number: 9272030Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.Type: GrantFiled: April 22, 2011Date of Patent: March 1, 2016Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLCInventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
-
Publication number: 20150118223Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.Type: ApplicationFiled: April 22, 2011Publication date: April 30, 2015Applicants: WYETH LLC, JANSSEN ALZHEIMER IMMUNOTHERAPYInventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
-
Publication number: 20140308302Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: May 29, 2014Publication date: October 16, 2014Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
-
Patent number: 8759495Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: GrantFiled: August 11, 2011Date of Patent: June 24, 2014Assignee: Wyeth LLCInventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
-
Publication number: 20130209453Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.Type: ApplicationFiled: April 22, 2011Publication date: August 15, 2013Applicants: WYETH LLC, JANSSEN ALZHEIMER IMMUNOTHERAPYInventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini
-
Publication number: 20120276102Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Applicant: WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Publication number: 20120264919Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: April 23, 2012Publication date: October 18, 2012Applicants: MEDIMMUNE LIMITED, WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
-
Patent number: 8178097Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: May 15, 2012Assignee: Wyeth LLCInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, Margot O'Toole, Heath M. Guay, Karissa K. Adkins, Amy Arlene Weaver, Sadhana Jain, Maya Arai
-
Patent number: 8163884Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: April 24, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, David Lowe, Viia Valge-Archer
-
Publication number: 20120070379Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.Type: ApplicationFiled: September 13, 2011Publication date: March 22, 2012Applicants: Janssen Alzheimer Immunotherapy, Wyeth LLCInventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
-
Publication number: 20120064600Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: August 11, 2011Publication date: March 15, 2012Applicant: WYETH LLCInventors: Erwin R. BOGHAERT, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
-
Publication number: 20110262435Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: May 2, 2011Publication date: October 27, 2011Applicant: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Patent number: 8044178Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: GrantFiled: March 9, 2007Date of Patent: October 25, 2011Assignee: Wyeth LLCInventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar
-
Patent number: 7943342Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: GrantFiled: January 22, 2009Date of Patent: May 17, 2011Assignee: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20100266505Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.Type: ApplicationFiled: October 17, 2008Publication date: October 21, 2010Applicants: Wyeth LLC, Janssen Alzheimer ImmunotherapyInventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
-
Publication number: 20090298167Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 26, 2009Publication date: December 3, 2009Applicants: WYETH, MEDIMMUNE LIMITEDInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
-
Publication number: 20090298081Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 26, 2009Publication date: December 3, 2009Applicant: WYETHInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Publication number: 20090274705Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: January 22, 2009Publication date: November 5, 2009Applicant: WYETHInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20090258005Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: May 29, 2008Publication date: October 15, 2009Applicants: Trubion Pharmaceuticals Inc., WyethInventors: Davinder Gill, Fionnuala McAleese, Peter A. Thompson, Peter R. Baum, Paul A. Algate
